A new approach to disease-modifying drug trials in Parkinson's disease

Journal of Clinical Investigation

Volumn 123, Issue 6, 2013, Pages 2364-2365

  Barker, Roger A ^a   Stacy, Mark ^b   Brundin, Patrik ^c,d  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VAN ANDEL INSTITUTE   (United States)

^d LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2 BROMO N (2 CHLOROETHYL) N ETHYLBENZYLAMINE; EXENDIN 4; LIPOPOLYSACCHARIDE; NEUROTROPHIC FACTOR; OXIDOPAMINE; PLACEBO;

BRADYKINESIA; CLINICAL TRIAL (TOPIC); DOPAMINERGIC NERVE CELL; ENCEPHALITIS; HOSPITAL PHARMACY; HUMAN; PARKINSON DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLACEBO EFFECT; PRIORITY JOURNAL; REVIEW; RIGIDITY; TREMOR;

ANTIPARKINSON AGENTS; FEMALE; HUMANS; MALE; PARKINSON DISEASE; PEPTIDES; VENOMS;

EID: 84878566284     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI69690     Document Type: Review

References (21)

1. Aviles-Olmos I, et al. Exenatide and the treatment of patients with Parkinson's disease. J Clin Invest. 2013;123(6):2730-2736.
2. Harkavyi A, Whitton PS. Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection. Br J Pharmacol. 2010;159(3):495-501.
3. Schapira AH, Jenner P. Etiology and pathogenesis of Parkinson's disease. Mov Disord. 2011; 26(6):1049-1055.
4. Dickson DW, et al. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol. 2009;8(12):1150-1157.
5. Barker RA, Barrett J, Mason SL, Bjorklund A. Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease. Lancet Neurol. 2013;12(1):84-91.
6. Kordower JH, Bjorklund A. Trophic factor gene therapy for Parkinson's disease. Mov Disord. 2013; 28(1):96-109.
7. Bjorklund T, Kordower JH. Gene therapy for Parkinson's disease. Mov Disord. 2010; 25(suppl 1):S161-S173.
8. de la Fuente-Fernández R, Schulzer M, Mak E, Sossi V. Trials of neuroprotective therapies for Parkinson's disease: problems and limitations. Parkinsonism Relat Disord. 2010;16(6):365-369.
9. Harkavyi A, Abuirmeileh A, Lever R, Kingsbury AE, Biggs CS, Whitton PS. Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. J Neuroinflammation. 2008;5:19.
10. Li Y, et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci U S A. 2009;106(4):1285-1290.
11. Rampersaud N, Harkavyi A, Giordano G, Lever R, Whitton J, Whitton PS. Exendin-4 reverts behavioural and neurochemical dysfunction in a pre-motor rodent model of Parkinson's disease with noradrenergic deficit. Br J Pharmacol. 2012; 167(7):1467-1479.
12. Bertilsson G, et al. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J Neurosci Res. 2008;86(2):326-338.
13. Olanow CW, et al. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord. 2008;23(15):2194-2201.
14. Olanow CW, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009;361(13):1268-1278.
15. Fahn S, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004;351(24):2498-2508.
16. Galpern WR, et al. Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. Lancet Neurol. 2012;11(7):643-650.
17. Gill SS, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med. 2003;9(5):589-595.
18. Whone AL, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REALPET study. Ann Neurol. 2003;54(1):93-101.
19. Breen DP, Rowe JB, Barker RA. Role of brain imaging in early parkinsonism. BMJ. 2011;342:d638.
20. LeWitt PA, et al. AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, shamsurgery controlled, randomised trial. Lancet Neurol. 2011;10(4):309-319.
21. Marks WJ Jr, et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2010;9(12):1164-1172.